Kashiv生物科学组织与Intas和协议合作,为印度、欧洲和联合王国带来负担得起的生物相似物。 Kashiv BioSciences partners with Intas and Accord to bring affordable biosimilars to India, Europe, and the UK.

Kashiv生物科学与印度的Intas制药公司达成了独家许可和供应协议, Kashiv BioSciences has struck an exclusive licensing and supply deal with India’s Intas Pharmaceuticals to commercialize a complex peptide product in India, Europe, and the UK. Kashiv将管理监管登记、制造和供应,Intas及其联合王国的附属协议保健将处理分配和商业化问题。 Kashiv will manage regulatory registration, manufacturing, and supply, while Intas and its UK subsidiary Accord Healthcare will handle distribution and commercialization. 合作伙伴关系旨在扩大在关键市场获得负担得起的高质量的疗法,将Kashiv的生物类似药专业知识与Intas的全球影响力和Accord在仿制药和生物类似药方面的强大影响力结合起来. The partnership aims to expand access to affordable, high-quality therapies in key markets, combining Kashiv’s biosimilars expertise with Intas’s global reach and Accord’s strong presence in generics and biosimilars.